IL6 and COVID-19: Similarly, the tenth edition of China’s COVID–19 Diagnosis and Treatment Plan (PRC and Medicine, 2023) recommends the use of TCZ in severe and critical cases with markedly elevated IL–6 levels, allowing up to two cumulative doses.